[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,91,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100634918","single-arm-monocentric-pilot-feasibility-study-on-an-interactive-virtual-reality-program-in-20-complex-in-clinic-palliative-care-patients-100634918",false,"NCT07545928","Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients","ZENCTUARY_VR+","Inclusion Criteria:\n\n* Patient ≥ 18 years old, hospitalized at the USP - HUS\n* Estimated life expectancy ≥ 1 month (Pronopall score based on clinical data).\n* Montreal Cognitive Assessment (MoCA) scale score ≥ 26.\n* Able to understand the objective and risks of the study\n* VRISE score ≤ 25 after the VR familiarization procedure\n* Affiliation with the Social Security system or beneficiary of such social protection.\n* Signed consent from, able to understand and complete the questionnaires in French.\n\nExclusion Criteria:\n\n* Patients with psychiatric disease\n* Patients under court protection\n* Uncontrolled epilepsy\n* Visual impairments (lack of binocular vision, blindness) and\u002For hearing impairments (deafness) preventing the use of virtual reality","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Palliative care patients frequently face a \"symptom cluster\" of pain (up to 96%), fatigue (up to 90%), and anxiety (up to 79%), which severely degrades their quality of life in their final months.The study is built on the concept of passive exposure therapy (VREP), which engages multiple senses to distract the brain from pain signals. By creating an \"immersive distraction\" or a \"flow state,\" VR can activate the brain's reward networks and reduce activity in areas associated with pain perception. Unlike most existing VR research in palliative care which uses \"passive\" VR (like watching a 360-degree video), this study uses interactive VR. Patients can perform simple actions-like grabbing or dropping virtual objects-within a calming natural environment, which may better support their sense of autonomy and dignity. Because this is a pilot study, the \"Go\u002FNo-Go\" decision for future larger trials depends on a strict composite of three factors:\n\n* Adherence: The patient must complete at least 11 out of 14 planned daily sessions.\n* Duration: Each session must average at least 7.5 minutes of usable VR exposure.\n* Tolerance: The patient must experience no device-related serious adverse events and maintain a high average tolerance score (VRISE score ≥ 25).",[26,27,28,29,30,31],"Palliative Care","Refractory Pain","Anxiety","Depression Disorders","Fatigue, Mental","Psychological Distress",[33,34,35,36,37,38,39],"palliative care","end-of-life care","refractory pain","Interactive Virtual Reality","Immersive Technology","Virtual Reality Exposure Therapy (VRET)","Cybersickness in Palliative Care","NOT_YET_RECRUITING","2026-04-15",{"date":43,"type":44},"2026-04-22","ACTUAL",{"date":46,"type":20},"2026-09-01",{"date":48,"type":20},"2027-03-01",{"name":50,"class":51},"University Hospital, Strasbourg, France","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":52},"100471350","patients-referred-to-the-chronic-pain-unit-for-palliative-treatment-with-ozone-therapy-between-2022-and-2025-100471350","NCT05417737","Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025","Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025. (EPOOzo)","EPOOzo","Inclusion Criteria:\n\n1. Adults \\> = 18 years old.\n2. Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín for symptomatic\u002Fpalliative treatment with ozone therapy because conventional treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.\n3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.\n4. Patients have no contraindications for ozone treatment.\n5. Patients have signed and dated the informed consent for the compassionated ozone treatment and the specific informed consent for this study\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years old.\n2. Psychiatric illness or social situations that would limit compliance with study requirements.\n3. Those who are incapable to fill in the scales used to measure variables.\n4. Hemodynamically or clinically unstable patients or uncontrolled severe illness.\n5. Uncontrolled cancer disease requiring chemotherapy treatment.\n6. Life expectancy \\\u003C 6 months\n7. Contraindication or disability or to attend scheduled treatments.\n8. Known allergy to ozone.\n9. Pregnancy at the time of enrollment (for systemic ozone therapy). 10 Hemochromatosis (for systemic ozone therapy).\n\n11\\. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy).\n\n12\\. Patients who do not meet all the inclusion criteria",{"count":62,"type":20},105,"28 Weeks","OBSERVATIONAL","The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025",[67,68,69,70,71,27],"Radiation Toxicity","Chemotherapeutic Toxicity","Chemotherapy-induced Peripheral Neuropathy","Delayed Wound Healing","Chronic Pain",[69,73,74,75,76,77,78,79,80],"Radiation-induced toxicity","Cancer-treatment side effects","Delayed wound healing","Chronic pain","Health-related quality of life","Anxiety and Depression","Ozone therapy","Refractory pain","RECRUITING","2025-08-25",{"date":84,"type":44},"2025-09-02",{"date":86,"type":44},"2022-06-15",{"date":88,"type":20},"2026-06-30",{"name":90,"class":51},"Bernardino Clavo, MD, PhD",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":100,"studyType":64,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100387182","op2c--prialt-observatory-in-clinical-practice-100387182","NCT04321408","OP2C : Prialt® Observatory in Clinical Practice","OP2C","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Severe refractory chronic pain requiring intrathecal analgesia\n* Candidate for intrathecal analgesia treatment with ziconotide\n* Patient informed about the study and agreeing to take part in.\n\nExclusion Criteria:\n\n* Contraindications to ziconotide",{"count":99,"type":20},300,"4 Years","Ziconotide is a strong analgesic marketed since 2005 in Europe and reserved for the intrathecal route. Its efficacy has been proven in particular by 3 randomized clinical studies.\n\nIt is particularly effective on neuropathic pain and its main advantages are its power of action, the absence of bone marrow toxicity, and the absence of respiratory depression. In addition, there were no signs of withdrawal when stopping the drug, or of tachyphylaxis.\n\nHowever, during these studies many adverse reactions were highlighted, especially neuropsychiatric which limited its use. This toxicity was mainly related to the administration of too high doses, especially at the start of treatment (too fast titration).\n\nIn recent years, the use of intrathecal ziconotide has become a pertinent option. Indeed, it is recommended as first-line among the intrathecal treatment options.\n\nHowever, there is a lack of data on the current use of ziconotide in current practice.\n\nThe objective of the study will be to describe the practical methods of using intrathecal treatments containing ziconotide.",[27],[104,105],"Intrathecal analgesia","Ziconotide","2025-08-13",{"date":108,"type":44},"2025-08-17",{"date":110,"type":44},"2020-07-10",{"date":112,"type":20},"2027-09",{"name":114,"class":51},"Institut Cancerologie de l'Ouest",17,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100575999","fluoroscopic-guided-bipolar-versus-monopolar-pulsed-radiofrequency-for-refractory-trigeminal-neuralgia-100575999","NCT06779578","Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia","The Efficacy and Safety of Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia: An Exploratory Study","Inclusion Criteria:\n\n1. Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).\n2. Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.\n3. Patients with idiopathic TN, with symptomatic clinical topography of V2 and\u002For V3.\n4. Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.\n5. Patients with medically refractory TN defined as pain persisting beyond three months at a level of ≥5\u002F10 after monotherapy or polytherapy in appropriate medical doses.\n\nExclusion Criteria:\n\n1. Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).\n2. Trigeminal neuralgia with V1 symptomatic clinical topography.\n3. Trigeminal neuralgia comorbid with other atypical facial pain disorders.\n4. Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, …etc.\n5. Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.\n6. Patients who refused to participate in the study.",{"count":19,"type":20},[23],"A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.",[127,27],"Trigeminal Neuralgia",[129,130,131,132,133],"trigeminal neuralgia","Radiofrequency ablation","Pulsed radiofrequency","Monopolar pulsed radiofrequency","Bipolar pulsed radiofrequnency","2025-01-16",{"date":136,"type":44},"2025-01-17",{"date":138,"type":44},"2024-01-01",{"date":140,"type":20},"2025-09-01",{"name":142,"class":51},"Alexandria University",2]